ABOUT FLOURISH RESEARCH
Flourish Research is a fully integrated, multi-site clinical trial network serving sponsors and CROs across North America. We conduct Phase I–IV studies in cardiovascular, metabolic, and oncology, and CNS indications, delivering best-in-class quality, expert scientific leadership, and predictable recruitment at scale.
INDUSTRY INSIGHTS
-
![clinical-trials-cns-GettyImages-2217864525]( "The Innovations Shaping 2026 CNS Clinical Trials")
Explore how AI, digital tools, and site‑centered design can reduce burden, strengthen data quality, and support more reliable trial execution.
-
![diabetic-clinical-research-GettyImages-1280028815]( "Phase 1 Trial In Painful Diabetic Peripheral Neuropathy")
A complex Phase 1 neuropathy study with overnight stays achieved full enrollment and retention through careful planning, strong participant engagement, and disciplined operational execution.
-
![brain-scan-GettyImages-2160716915]( "Leading Recruitment With A Strong Alzheimer's Referral Pool")
A strong referral network helped the Gainesville site rapidly recruit pTau217‑positive Alzheimer’s participants while upholding high data quality, boosting enrollment and outperforming other sites.
-
![alzheimers-patient-GettyImages-2182295717]( "Reduction Of Screen Failures In A Biomarker")
Targeted prescreening for biomarker and cognitive criteria cut screen failures in a complex Alzheimer’s trial, speeding enrollment and improving site efficiency while maintaining strict eligibility.
-
![patient-voice-mental-health-GettyImages-1975794314]( "Turning Innovation Into Execution In CNS Trials")
SCOPE 2026 experts called for practical planning, iterative testing, and real‑world workflows in mental health research, highlighting mock visits, expanded roles, engagement, and psychedelic safety.
CONTACT INFORMATION
Flourish Research
3675 Green Level Road West, Suite 208
Apex, NC 27523
UNITED STATES
SOLUTIONS
-
![clinical-sites-GettyImages-2057440780]( "A Premier Site Network For High-Performance Trials")
A national research network with advanced facilities, expert investigators, and diverse patients to support efficient Phase I–IV trials and speed complex protocols and enrollment.
